Immune response and epitope mapping of a candidate HIV-1 p17 vaccine HGP30

J Clin Lab Anal. 1990;4(1):43-7. doi: 10.1002/jcla.1860040109.

Abstract

A thirty amino acid synthetic peptide (HGP30) representing the conserved region of HIV-1 p17 induced high titer antibodies to the native p17 in rabbits. This immune sera neutralized HIV-1 replication in cell culture and one of the high titer antisera also inhibited CD4-dependent cell fusion. Pepscan analysis with overlapping nonapeptides derived from the sequence of HIV-1 p17 identified the sequence (KE) ALDKIEE (EQ) as the major antibody binding site. Sera of 9% of AIDS patients (7/76) and 18% of HIV-1 seropositive healthy homosexuals (40/223) were positive for HGP30 antibodies. Decline in HIV-1 p17 antibodies has been shown to be related to disease progression in both children and adults, suggesting that HIV-1 p17 antibodies may be protective. Hence, a synthetic HIV-1 p17 peptide, representing the immunodominant epitope, could be useful as a candidate vaccine for immunization of HIV-1 seronegative or seropositive healthy homosexuals.

MeSH terms

  • Acquired Immunodeficiency Syndrome / prevention & control
  • Amino Acid Sequence
  • Animals
  • Binding Sites
  • Epitopes
  • HIV Antibodies / biosynthesis*
  • HIV Antigens / immunology*
  • HIV Seropositivity / immunology
  • Humans
  • Molecular Sequence Data
  • Peptides / immunology*
  • Rabbits
  • Viral Vaccines / immunology*
  • Viral Vaccines / therapeutic use
  • gag Gene Products, Human Immunodeficiency Virus

Substances

  • Epitopes
  • HGP-30 peptide, Human immunodeficiency virus-1
  • HIV Antibodies
  • HIV Antigens
  • Peptides
  • Viral Vaccines
  • gag Gene Products, Human Immunodeficiency Virus